- Welcome and Introduction
- MDS Classification Schemes and Pathology Workup
- The Pathologists’ Assessment of Ring Sideroblasts and SF3B1 Mutations
- “Tying It All Together” Case Discussion: Evidence-Based Treatment Strategies for MDS-RS and MDS/MPN-RS-T
- Key Takeaways
- Audience Question and Answer
Date / Time
New Orleans, LA
Hyatt Regency New Orleans
Tal Oren, MD, PhD
Alexa J. Siddon, MD
Associate Professor, Laboratory Medicine and Pathology
Hematopathology Fellowship Director
Yale School of Medicine
New Haven, Connecticut
Cecilia Yeung, MD
Clinical Research Division
Fred Hutch Cancer Center
University of Washington
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to accurately diagnose and provide evidence-based treatment strategies for patients with MDS-RS and MDS/MPN-RS-T.
This educational program is intended for pathologists, hematopathologists, hematologists, hematologists/oncologists, and other healthcare professionals involved in precision care of MDS.
Upon completion of this activity, participants should be able to:
- Formulate an actionable diagnostic workup plan for MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis considering ring sideroblast quantification and evaluation, current guidelines, and clinical evidence
- Ascertain the clinical rationale for SF3B1 testing combined with ring sideroblast assessment in the diagnosis of MDS, based on the currently available data, guidelines, and expert recommendations
- Identify technologies available to pathologists that can be used to test for SF3B1 mutations
- Integrate into practice adequate sampling and sampling types for the accurate diagnosis of MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis to guide treatment decisions
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.